Jenn Habeck

Pharmacokinetics and safety of rucaparib in patients with advanced solid tumors and hepatic impairment

Y. Drew, R. Dziadziuszko, R. Ramlau, 2021, Cancer Chemotherapy and Pharmacology.

Phase Ib SEASTAR Study: Combining Rucaparib and Sacituzumab Govitecan in Patients With Cancer With or Without Mutations in Homologous Recombination Repair Genes

G. Shapiro, T. Yap, R. Jeselsohn, 2022, JCO precision oncology.

Abstract 445: Genomic characteristics and response to rucaparib and enzalutamide in the phase 1b RAMP study of metastatic castration-resistant prostate cancer (mCRPC) patients

C. Ryan, V. Assikis, Jim J. Xiao, 2021, Clinical research.

Rucaparib plus enzalutamide in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Pharmacokinetics (PK) and safety data from the phase Ib RAMP study.

D. Morris, C. Ryan, V. Assikis, 2021 .

A phase 1, open-label, drug–drug interaction study of rucaparib with rosuvastatin and oral contraceptives in patients with advanced solid tumors

R. Ramlau, I. Láng, M. Liao, 2021, Cancer Chemotherapy and Pharmacology.